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ABSTRACT
Objective: To assess whether shared medical appointments (SMAs) for neuromuscular patients
represent a way of using clinicians’ time efficiently without compromising quality of care for
patients.
Methods: Patients with a chronic neuromuscular disease (NMD) (n 5 272) were randomly allo-
cated to either an SMA or a regular individual annual appointment and followed up for a period of
6 months. Data on resource utilization and quality of life (EQ-5D) were collected prospectively,
using a health care perspective. Incremental costs and changes in quality-adjusted life-years
(QALYs) were computed using a probabilistic decision model. Factors critical to the incremental
cost-effectiveness of SMAs were explored in sensitivity analyses.
Results: No substantial differences between SMAs and individual visits in terms of costs per
QALY were found (incremental cost-effectiveness ratio €2960.00; 95% confidence interval
€234,600.00, €136,800.00). Sensitivity analyses showed that the cost-effectiveness ratio
was particularly sensitive to SMA group size and proportion of patients seeing their treating
neurologist.
Conclusions: Cost-effectiveness of SMAs did not show a significant difference vs that of individ-
ual appointments based on data from our randomized controlled trial. On the other hand, we were
able to show that a minimum of 6 patients per SMA and 75% of patients attending their treating
neurologist are specific conditions under which SMAs qualify as a cost-effective alternative. This
implies that SMAs may be a means to increase productivity of the physician without compromis-
ing quality of care.
Classification of evidence: This study provides Class III evidence that SMAs are not significantly
more cost-effective than individual appointments for patients with NMDs. The study lacks the
precision to exclude important differences in cost-effectiveness between SMAs and individual
appointments. Neurology® 2015;85:619–625
GLOSSARY
ICER 5 incremental cost-effectiveness ratio; NMD 5 neuromuscular disease; QALY 5 quality-adjusted life-year; RCT 5
randomized controlled trial; SMA 5 shared medical appointment.
Time is a precious resource in the context of patient care.1 Patients hope to find attentive
concern on the part of the clinician. On the other hand, in the interest of cost control, less
rather than more time per patient is available. The fact that productivity gains in health care do
not match those in other areas is an important factor contributing to the rise in health care
costs.2 The resulting increase in time pressure is not always experienced in the same way.
Clinicians who became patients realized how time can be experienced differently.3 Recognizing
these developments in our own department, we wondered whether shared medical appoint-
ments (SMAs) (where multiple patients and their partners with the same diagnosis are seen by
the neurologist at the same time) might help to resolve this problem. In a way, this creates more
clinician time for the patient, although not exclusively for him or her individually. Also, the
patient may benefit from knowledge and experiences of other patients, contributing to a
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decrease in resource utilization.4,5 To be sure,
there is a tradeoff, since some patients may
prefer not to discuss certain issues in the pres-
ence of others. We evaluated this approach in a
randomized controlled trial (RCT).6 In this
complementary article, we report the results
on resource use and quality of life. In a deci-
sion analytic model, we explored under which
conditions SMAs for this patient population
might qualify as an efficient and effective
option.
METHODS Standard protocol approvals, registrations,
and patient consents. This RCT was approved by the regional
medical ethics committee and written informed consent was
obtained from all participants. The trial is registered with the
Dutch Trial Register (www.trialregister.nl) as NTR1412.
Study design. The study comprises an economic evaluation from
the health care perspective and was conducted in parallel with an
RCT. The methods and results pertaining to the clinical effective-
ness of the RCT have been described in detail elsewhere.6,7 In brief,
we conducted an RCT with a 6-month follow-up where patients
with neuromuscular disease (NMD) were randomized to either an
SMA or an individual appointment with one of the 2 participating
neuromuscular neurologists (B.G.M.v.E., G.D.) at the outpatient
clinic of the Neurology Department of the Radboud University
Medical Centre.
The primary research question was to evaluate whether a
single SMA is more cost-effective for patients with chronic
neuromuscular disorders as compared to individual medical
appointments.
The secondary research questions were to analyze under which
conditions SMAs for patients with NMDqualify as an efficient and
effective alternative to individual appointments and what effect
SMAs have on the productivity of participating neurologists.
This study provides Class III evidence on whether SMAs are
more cost-effective than individual appointments for patients
with NMDs.
Participants. Patients were identified through the Computer
Registry of All Myopathies and Polyneuropathies (CRAMP),
the Dutch database of patients with NMD, and recruited
between March 2009 and March 2011.8 Patients were eligible
when they were diagnosed with one of the selected chronic
NMDs (table 1), were over 18 years of age, were currently in
the care of our department, and had not seen their neurologist 6
months prior to study commencement. Patients were recruited
from the practice of the study neurologists (B.G.M.v.E., G.D.) as
well as from colleague neurologists of our department. Exclusion
criteria were severe hearing problems or insufficient command of
the Dutch language.7 Eligible patients were invited to participate
together with their partners or chief informal caregiver.
Randomization. Patient randomization (1:1) was computer-
generated (by dedicated software), concealed, and balanced for
diagnoses. Due to the nature of the intervention, physicians
and participants could not be blinded to group assignment, but
the statistician who conducted the analyses was blinded to
treatment allocation.
Intervention. Patients and partners randomized to the SMA
group were invited to attend an SMA of 1.5–2 hours as a substi-
tute for their regular annual visit. During an SMA, 1 of 2 spe-
cialist neurologists (either B.G.M.v.E. or G.D.) saw 5–8 patients
with the same diagnosis and their partners simultaneously,
addressing the same topics that are commonly covered during
the yearly follow-up appointment. The neurologist was supported
by a group mentor who facilitated the group process by fostering
interaction between patients and partners and by managing time.
Table 1 Baseline participant characteristics for the 2 study groups
Shared medical
appointment
(n 5 123)
Individual
appointment
(n 5 112)
Age, y, mean (SD) 50 (13.5) 52 (13.3)
Men 63 (51.2) 62 (55.4)
Partner relationship 86 (70.5) 79 (72.5)
Diagnoses
Myotonic dystrophy type 1 45 (36.6) 30 (26.8)
Facioscapulohumeral muscular dystrophy 24 (19.5) 23 (20.5)
Nondystrophic myotonias: chloride and sodium
channelopathies
9 (7.3) 12 (10.7)
Myositis: dermatomyositis and polymyositis 7 (5.7) 12 (10.7)
Polyneuropathy 14 (11.4) 15 (13.4)
Inclusion body myositis 4 (3.3) 5 (4.5)
Chronic progressive external ophthalmoplegia 4 (3.3) 1 (0.9)
McArdle disease 5 (4.1) 3 (2.7)
Oculopharyngeal muscular dystrophy 11 (8.9) 11 (9.8)
Modified Rankin Scale score (higher scores
indicate more severe symptoms)
0 4 (3.4) 8 (8.2)
1 19 (16.0) 13 (13.4)
2 39 (32.8) 35 (36.1)
3 21 (17.6) 14 (14.4)
4 34 (28.6) 27 (27.8)
5 2 (1.7) 0 (0)
Employment status
Studying/in training 2 (1.7) 2 (1.9)
Paid work 42 (36.5) 33 (31.1)
Housework/volunteer work 8 (7.0) 7 (6.6)
Seeking work 2 (1.7) 1 (0.9)
(Partially) medically retired 36 (31.3) 37 (34.9)
Retired 25 (21.7) 26 (24.5)
Self-reported comorbidity 85 (70.2) 65 (60.2)
Cardiac symptoms 19 (15.8) 16 (15.2)
Depression 11 (9.2) 3 (2.9)
Eye/stare symptoms 20 (16.7) 14 (13.3)
Gastroenterologic disease 28 (23.2) 20 (19.0)
Pain 24 (20.0) 15 (14.3)
Thyroid symptoms 6 (5.0) 2 (1.9)
Appointment with treating neurologist 20 (16.3) 34 (30.6)
EQ-5D index, median (interquartile range) 0.78 (0.65–0.81) 0.78 (0.65–0.81)
Data are n (%) unless stated otherwise.
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Both neurologists and the group mentor had received training in
conducting SMAs prior to the study.
Participants randomized to the control group were seen indi-
vidually by one of the participating neurologists (B.G.M.v.E. or
G.D.) during their regular annual 20-to-30-minute appointment.
For both intervention groups, care was tailored to the needs of the
patients and their partners. Prescriptions, referrals, and medical
record-keeping were as usual.
Outcome measures. Utilities were evaluated by the EuroQol
EQ-5D index scale for patients, a standardized instrument
designed to determine health-related quality of life in terms of
quality-adjusted life-years (QALYs).9 To measure the use of
resources, the following items from the Client Service Receipt
Inventory10 were included: visits to a general practitioner,
medical specialist, physiotherapist, occupational therapist,
psychologist, psychiatrist, or social worker; hospital admissions;
medication; home care and domestic help.
Outcome measures were obtained through self-reported ques-
tionnaires unless stated otherwise. Participants received these by
mail at home 4 weeks before and 1, 12, and 24 weeks after the
intervention. Severity of disease according to the modified Rankin
Scale was established by physicians during the appointments.
Valuation of the cost items. Costs were calculated by multi-
plying volumes of resources by the cost price per resource unit
(table 2). Cost prices were based on the Dutch guidelines for
economic evaluation in health care unless stated otherwise.11
Domestic help was quantified in hours worked, adopting national
average hourly wage rates for domestic cleaners. All prices were
converted to the year 2011 by means of the Dutch consumer
price index and expressed in euros (at which time 1 euro was
equivalent to British £0.85 and USD $1.31).12
Intervention costs. Since no unit cost price was available for
SMAs, we calculated SMA cost price on the basis of the actual
time spent by the consultant neurologist and group mentor
(a specialist nurse or equivalent). Cost prices of the health profes-
sionals’ time were based on the Dutch guidelines for economic
evaluation in health care and converted to 2011 corresponding
with the valuation of the cost items.11 No adjustments were made
for the number of patients per SMA since this did not affect its
organization or duration.
Statistical analysis. Descriptive statistics were used to generate
baseline participant characteristics. Participant data were included
for analysis when at least the baseline and 1 effect measurement
was available. Remaining missing patient data on the volumes
of resources used and QALYs were imputed with multiple impu-
tation techniques.13 Imputation was executed 5 times and the
weighted means of cost variables and effects over the follow-up
time were calculated. QALYs were calculated from baseline to
follow-up (6-month periods) using the area under the curve
method and compared with a t test. Analyses were conducted
on the basis of the intention-to-treat principle. A p value
of ,0.05 was regarded as significant and SPSS was used to
conduct the analyses of total costs and QALYs.
Probabilistic decision model. To compare the cost-effectiveness
of an SMAwith an individual appointment, a probabilistic decision
model was developed. The model consisted of 2 main branches,
SMA and individual appointment, each allowing for the
probability that a patient was seen by his own neurologist or not.
(See figure e-1 on the Neurology® Web site at Neurology.org for a
schematic figure of the model structure.) Model parameters for
expected costs (in euros) and effects (in QALYs) as well as
number of patients per SMA were extracted from the results of
Table 2 Cost variables, resources used, mean price per unit, and average costs per patient for the shared and the individual appointment
groups
Average no. of resources
used during follow-up, total
no. of units/N
Unit cost price, €,
2011
Mean (range) cost per patient during follow-up, €, total costs per
units/N
SMA
Individual
appointment SMA Individual appointment
Intervention — — 104.50 131.71a
General practitioner (visits) 2.0 1.6 28.59a 57.11 (0–686.11) 45.96 (0–343.06)
Medical specialist (visits) 1.7 1.8 73.51a 126.58 (0–882.14) 133.80 (0–1,396.73)
Physiotherapist (visits) 14.3 17.0 36.76a 525.64 (0–3,528.58) 623.96 (0–3,675.60)
Occupational therapist (visits) 1.2 1.1 22.46a 27.34 (0–899.33) 24.41 (0–808.63)
Social work (visits) 0.4 0.1 66.37a 25.61 (0–1,128.21) 9.79 (0–464.56)
Psychologist (visits) 0.2 0.2 81.68a 20.24 (0–1,143.52) 18.20 (0–816.80)
Psychiatrist (visits) 0.11 0.02 105.68a 11.90 (0–1,056.78) 2.09 (0–211.36)
Hospital admissions (no. of nights) 0.6 1.2 466.60a 280.12 (0–7,465.55) 543.89 (0–14,464.51)
Medication (dosages) 31.7 38.9 Variableb 36.71 (0–250.18) 36.72 (0–364.52)
Home care (hours) 2.3 1.3 35.91a 82.12 (0–1,651.86) 46.25 (0–574.56)
Domestic help (hours) 1.5 2.3 12.5 18.86 (0–262.50) 29.22 (0–500.00)
Total costs 1,317.44 (104.50–8,846.16) 1,646.89 (131.71–16,221.05)
Abbreviation: SMA 5 shared medical appointment.
Mean costs based on pooled data from 5 imputed datasets.
aUnit cost prices derived from the Dutch guidelines for health economic evaluations (Hakkaart-van Roijen et al., 201011).
bUnit cost prices as derived from the Dutch list of drug costs (www.medicijnkosten.nl).
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our RCT for both treatment groups (table 3). The incremental
cost-effectiveness ratio (ICER) was calculated and represented
visually as an incremental cost-effectiveness scatterplot showing
pairs of incremental cost and effectiveness values from n 5 1,000
iterations. The probability that an SMA is cost-effective was
calculated using a willingness-to-pay of €80,000.00 per QALY, a
threshold suggested by the Council for Public Health and Health
Care of TheNetherlands.14 The impact of model parameters on the
ICER were explored in 1-way and 2-way sensitivity analyses.
TreeAge Pro and Microsoft Excel were used to conduct the
decision modeling.
RESULTS Participants. In total, 272 patients were
included in the study, of whom 143 were randomly
assigned to the SMA group and 129 to the individual
appointment group. For 37 patients, fewer than 2
measurements were available, resulting in a total of
235 datasets for analysis. The patients in the 2 groups
were similar at baseline with respect to most variables
(table 1). In the SMA group, slightly more patients
were diagnosed with myotonic dystrophy type 1,
fewer patients were seen by their treating neurologist,
and slightly more patients reported comorbidity.
These differences were corrected for in the statistical
analyses.
Outcome. Volumes of resource use, unit cost prices,
and average costs for both groups are presented in
table 2. The pooled average cost of resources cumu-
lated over the 6-month follow-up period was
€1,317.44 (range €104.50–€8,846.16) per patient
for the SMA group and €1,646.89 (range €131.71–
€16,221.05) for the individual appointment group.
The mean QALYs over the 6-month follow-up period
for the SMA group was 0.69 (SE 0.14) and for the
individual appointment group 0.74 (SE 0.16).
Monte Carlo modeling. A Monte Carlo simulation re-
sulted in an incremental loss of 0.05 QALYs and a
€48 reduction in costs for the 6-month follow-up
period for the SMA/individual appointment contrast.
In other words, for 1 QALY lost, health care could gain
€960 per patient when SMAs would be implemented
(ICER 5 €2960.00; 95% confidence interval
€234,600.00, €36,800.00). The probability that
SMAs are more cost-effective than individual visits
was 39% at a willingness-to-pay of €80,000 (figure 1).
Sensitivity analysis. Costs appeared significantly influ-
enced by the number of patients per SMA and the
proportion of patients seen by their treating neurolo-
gist. One-way sensitivity analysis of number of
patients per SMA vs expected costs resulted in a
threshold value of 6.2 patients (figure 2). Two-way
sensitivity analyses of number of patients and
probability of being seen by the treating neurologist
showed that group visits can be more cost-effective
than individual visits provided that SMA groups
comprise more than 6 patients and that 75% of the
patients are seen by their treating neurologist (figure
not shown).
Productivity. With a mean of 16 minutes (range 11–
30), the neurologists spent less time per patient dur-
ing the SMAs, given that the individual appointments
lasted on average 25 minutes (range 20–30), as based
on the actual attendance rates during the study
period. Fewer than 8% of the patients required indi-
vidual attention in addition to the SMA, a proportion
that did not significantly influence the total time
spent per patient in the intervention group.
DISCUSSION Using data from our RCT in chronic
neuromuscular patients in a Monte Carlo simulation,
we did not find any substantial significant differences
between single SMAs and single conventional indi-
vidual visits in terms of costs per QALYs. On the
other hand, sensitivity analyses showed that a single
SMA was more cost-effective than an individual
appointment when a group size of more than 6
patients was maintained and 75% of these patients
were seen by their treating neurologist. We have
shown that if the abovementioned prerequisites
are met, SMAs have the possibility to improve
productivity for this specific population without
compromising quality of care. Shared appointments
are different in nature from one-on-one visits and
require a different approach and mindset from both
Table 3 Input parameters of the probabilistic decision model
Parameter
Expected
value SD 95% CI Source
Probability of attending treating
neurologist
SMA 0.75 0.04 0.67–0.83 Clinical experience
Individual appointment 0.90 0.03 0.83–0.95 Clinical experience
No. of patients per SMA 3–9 1 6–10 Empirical data
Total cost resources used, €
SMA
Treating neurologist €365 356 11–1,330 Empirical data
Other neurologist €828 1,057 2–3,655 Empirical data
Individual appointment
Treating neurologist €419 616 0–2,245 Empirical data
Other neurologist €1,198 1,876 0–6,397 Empirical data
Effectiveness (QALY)
SMA
Treating neurologist 0.67 0.18 0.29–0.96 Empirical data
Other neurologist 0.70 0.18 0.30–0.97 Empirical data
Individual appointment
Treating neurologist 0.73 0.18 0.30–0.98 Empirical data
Other neurologist 0.74 0.15 0.38–0.97 Empirical data
Abbreviations: CI 5 confidence interval; QALY 5 quality-adjusted life-year; SMA 5 shared
medical appointment.
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the attending consultant and the patient, but as
they provide patients an opportunity to share their
knowledge and experiences as well as more time with
their clinician, they may be more rewarding for
both the patient and health professionals involved.
However, we are aware that such advantages are
largely speculative and need to be explored and
substantiated in future studies.
Although several studies have reported a decline in
resource utilization associated with SMAs, our find-
ings suggest that no such savings should be expected
for the SMAs we evaluated during a 6-month follow-
up. This may be attributed to our distinctive diagno-
sis groups; the previous studies included patients with
more common diseases like diabetes and heart fail-
ure.4,5,15 Attending a 90-minute group appointment
with a neuromuscular neurologist and 6 to 8 peers
could provide patients with a rare NMD with a wider
variety of information and expertise, inducing more,
instead of fewer, initial referrals. This is illustrated by
the fact that resource utilization was significantly
higher for patients who normally attend a general
neurologist and during the study were seen by a spe-
cialized neuromuscular neurologist. Possibly under-
utilization of care is the case for several patients
with a rare NMD and SMAs could make specialist
care available to more patients. A potential decrease of
resource utilization should be assessed in the light of
fewer complications in the longer term.
We also offered the fact that we compared single
SMAs with single individual appointments as an
alternative explanation in our previous article; most
other studies evaluated series of SMAs.6,16–18 Resource
use might decrease after attending multiple SMAs,
while patients gain knowledge over time and most
referrals are being made during the first appointment.
Finally, although several authors emphasized that
maintaining a sufficient SMA group size is important
for both efficiency and interaction purposes, none
have evaluated its impact.17,19 With our study we have
shown that the cost-effectiveness of SMAs for NMD
outpatients is particularly sensitive to SMA group size
and to the proportion of patients seeing their treating
neurologist.
Figure 1 Incremental cost-effectiveness scatterplot of shared vs individual medical appointments
The incremental cost-effectiveness scatterplot includes a single set of points representing pairs of incremental cost and
effectiveness values from the simulation results (n 5 1,000) relative to a baseline. The slope intersecting the x axis is
the willingness-to-pay (WTP) threshold of €80,000. In addition to the WTP line, a 95% confidence ellipse is drawn in the
incremental cost-effectiveness scatterplot. The graph can be divided into 4 quadrants: southeast, shared medical appoint-
ments (SMAs) are less costly and more effective (SMAs dominate); southwest, SMAs are less costly and less effective;
northwest, SMAs are more costly and less effective (individual appointments dominate); northeast, SMAs are more costly
and more effective. The probability of SMAs being considered more cost-effective than individual appointments was 39%
at a WTP of €80,000. QALYs 5 quality-adjusted life-years.
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We performed an economic evaluation alongside a
sizeable RCT, the robust design of which enabled us
to align the intervention to usual care and to reliably
compare the cost-effectiveness of a single SMA to that
of an individual appointment.6 The wide range of
neuromuscular disorders included in our cohort is
reflective of clinical practice and enhances the gener-
alizability of our results. Additionally, all missing vol-
umes of resource use were imputed using multiple
imputation techniques, which have been shown to
be a reliable method for missing cost data.20 Then
again, opting for a societal point of view for this eco-
nomic evaluation may have strengthened the results,
although we conjectured that the effects would be
negligible. When interpreting the results it is impor-
tant to take into account that patients attending an
SMA together could influence each other. This could
result in clustering effects and overrate the effect of
the SMAs. Also, the self-reported comorbidity rates at
baseline were slightly higher in the SMA group. Cor-
recting for this slight imbalance in the analysis did not
affect the resource utilization in the 2 groups.
Another limitation is the study period; the 6-month
follow-up may have been too short a period to unveil
differences in costs, as it is plausible to assume that
the number of referrals for the patients attending
SMAs will drop after the initial group visit.
On a broad scale, controlled studies comparing the
economic benefits of health care innovations that
promote self-management skills in patients with a
neuromuscular disorder are limited and additional
RCTs with longer follow-up periods are needed to
determine their long-term cost-effectiveness. More spe-
cifically, the potential effect of SMAs on resource utili-
zation could be higher for patients for whom curative
treatment options are available alongside symptomatic
treatment. This would be an interesting question for
further studies in this area. Follow-up research should
also investigate which (groups of) patients benefit most
from SMAs and which variables, besides group size and
the proportion of patients seeing their own neurologist,
influence cost-effectiveness most.
Although we were unable to detect consistent sig-
nificant differences in terms of costs per QALY
between an SMA and an individual appointment
for chronic neuromuscular patients within the scope
of our investigations, our data provided evidence sug-
gesting that in this population the economic impact
of SMAs depends on group size and the proportion
of patients being seen by their own neurologist.
These conditions will concurrently help increase
the productivity of the consulting physician without
compromising quality of care. This adds important
data to our earlier results on the effectiveness of
SMAs for neuromuscular patients.6 Especially for rare
chronic diseases such as NMDs, group visits could
make high-quality outpatient care from a specialist
neurologist available for more patients while at the
same time empowering these patients and their part-
ners or informal caregivers by reinforcing their self-
management skills. However, before SMAs can be
more widely implemented, long-term effects on the
costs and possible working mechanisms will need to
be systematically explored and substantiated further.
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It’s Time to Plan for ICD-10, and the AAN Can Help
All health care providers are required to transition to ICD-10 on October 1, 2015. Claims for serv-
ices performed on or after this date with an ICD-9 code will not be processed and payments will be
delayed. The AAN provides information and resources to help you make this a smooth transition,
and has partnered with Complete Practice Resources to provide you with an affordable online pro-
ject management tool to help walk you through each phase of the necessary preparation to ensure
you’re ready. Learn more at AAN.com/view/ICD10 and start your transition today!
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